GABABR异二聚体和GBl-GBl同二聚体中的GBl亚基的作用

GABA水属于c族G蛋白偶联受体,是中枢神经细胞重要的抑制性神经递质受体。在体内GABAa_R由GBl和GB2两个基因编码,1998年以来研究者证实GABABR是由GBl和GB2形成的异二聚体,但近年来的研究表明,GBl也可以单独形成GBl-GBl同二聚体并在体内行使功能。本文系统介绍了GBl亚基的分类,在GB2存在或不存在时的表达,以及在GABAaR异二聚体和GBl．GBl同二聚体激活过程中所扮演的角色和生理功能;同时也展望了这些研究成果对于基础研究和药学研究的意义。关键词：GABA,~R：GBl：GB2：GBl．GBl同二聚体：激活机制     

GABAB受体活性调控机制的研究进展

γ-氨基丁酸B型受体(GABAB receptor,GABABR)是由GABAB1(GB1)和GABAB2(GB2)亚基组成的异源二聚体,在中枢神经系统中介导持久而缓慢的神经抑制活动。GABAB受体活性受多种因素的调控,如受体的胞内运输、受体的内吞和再循环、受体与胞内蛋白相互作用等,在神经元维持突触可塑性、产生快速神经抑制信号等方面起着非常重要的作用,其活性失调则导致自发性癫痫、痉挛药物成瘾、精神分裂症等多种严重疾病。     

RanBPM结合干扰素λ信号通路中的干扰素受体1

最新发现的干扰素λ表现出抗病毒、抗增殖和促凋亡活性,同I型干扰素一样干扰素λ结合干扰素λ受体复合体后进行信号传递.干扰素受体是由干扰素受体1和白介素10的受体2形成异二聚体,但是干扰素λ信号通路的分子调控机制仍不清楚.本研究分别运用谷胱甘肽巯基转移酶沉淀试验和免疫共沉淀试验证明了Ran蛋白的结合蛋白RanBPM与干扰素λ受体1相互作用.干扰素λ1能够促进干扰素λ受体1与RanBPM的相互作用和影响RanBPM在细胞内的分布.干扰素λ受体1与RanBPM的相互作用与保守的TRAF6的结合位点无关.RanBPM作为一个支架蛋白通过调控干扰素刺激反应元件的活性,是新的调控干扰素λ途径的蛋白.     

真核生物集缩素SMC2/SMC4异二聚体的结构解析研究进展

真核生物集缩素(condensin)的主要作用是在细胞周期过程中调控染色体的动态变化。它是一种含5个亚基的蛋白质,由1个起核心催化作用的SMC2(structure maintenance of chromosomes 2)/SMC4异二聚体和3个起调节作用的非SMC亚基组成。目前,关于集缩素中SMC2/SMC4异二聚体的体内构象和分子作用机制仍不清楚。最近,对SMC2/SMC4异二聚体的结构解析取得许多新进展。该文在简要介绍SMC蛋白的基本结构、真核生物集缩素的发现、真核生物集缩素的结构组成的基础上,对近年来SMC2/SMC4异二聚体的结构解析的研究进展作一综述,以期为相关研究提供参考。     

EB病毒潜伏膜蛋白1介导c-Jun/Jun B异源二聚体对cyclin D1的调节

研究发现LMP1可介导c-Jun/JunB活性异源二聚体的形成, 在此基础上, 利用建立的Tet-on系统调控LMP1表达的细胞系, 采用间接免疫荧光法联合激光共聚焦荧光显微镜技术、Western blot方法、荧光素酶活性检测、Super-EMSA方法和流式细胞术, 探讨LMP1介导c-Jun/Jun B异源二聚体对cyclin D1的调节功能. 结果表明, LMP1介导的c-Jun/Jun B异源二聚体可上调cyclin D1启动子活性及其表达, 并影响细胞周期的行进.     

一种新的转录因子--EPAS1

ＥＰＡＳ１是一种近年来被发现的转录蛋白,主要存在于内皮细胞内。ＥＰＡＳ１能与芳香烃受体核转移蛋白（ＡＲＮＴ）一起形成异二聚体,调节一系列基因的转录和表达,维持机体正常的生长和发育。     

XCR1与CXCR4形成异源二聚体并调控其内化

趋化因子及其受体信号通路是肿瘤细胞转移的主要调控因素之一,趋化因子受体CXCR4和XCR1都被证明参与了乳腺癌的进展。本文基于膜蛋白酵母双杂交发现了XCR1-CXCR4这一尚未报道过的相互作用对,进一步通过生物发光共振能量转移技术(bioluminescence resonance energy transfer, BRET)验证并发现XCR1可以竞争性地结合CXCR4受体 (P<0.01),形成异源二聚体。在功能方面,首先通过XCR1和CXCR4瞬时转染HEK293细胞进行划痕实验,加入30 nmol/L SDF-1β后,共转组41.55%的伤口愈合率低于单转CXCR4组的58.75%,说明XCR1的共表达抑制了基质细胞衍生因子-1β(SDF-1β)/ CXC趋化因子受体4型 (CXCR4)信号通路介导的细胞运动性(P<0.05);其次,利用CXCR4-EGFP转基因HEK293细胞系,共表达XCR1后,流式细胞术检测细胞表面CXCR4受体荧光。结果显示,在30 nmol/L SDF-1β的诱导下,XCR1能够加速异源二聚体中CXCR4的内化 (P<0.05),使得内化率从14.38%上升到64.10%;最后,分别检测了控制细胞增殖的Akt和控制细胞迁移的ERK信号通路的变化。结果发现,在SDF-1β刺激10 min后,单转CXCR4组的ERK磷酸化为3.59倍,而共转染XCR1/CXCR4组ERK的磷酸化水平仅为2.08倍,二聚化使得ERK磷酸化水平下降,且激活时间缩短;而Akt的磷酸化水平几乎不受影响。本研究揭示了CXCR4和XCR1二聚化现象,以及该二聚体对CXCR4介导的细胞运动性、受体内化和ERK磷酸化的影响。提示靶向XCR1的药物可以成为CXCR4交叉脱敏的候选药物,对于抑制乳腺癌转移提供了一个可供选择的思路。     

异育银鲫GABAB受体1亚基 cDNA部分序列的克隆及组织表达分析

为了确定γ-氨基丁酸B受体（gamma-aminobutyric acid B receptor,GABABR）基因在异育银鲫（Carassius auratus gibelio）不同组织中的表达,本实验分别对异育银鲫不同组织中GABABR1基因进行RT-PCR扩增,并进行了克隆和测序,在与GenBank基因库中已知GABABR1序列进行同源性比对的基础上采用邻接法构建系统发育树,并进一步分析其在异育银鲫不同组织内的表达水平。结果：经克隆获得异育银鲫GABABR1基因CDS区序列383bp,编码127个氨基酸。荧光定量PCR结果显示GABABR1基因在异育银鲫脑、肝、肾、心、肠、鳔、鳃、肌、鳍、脾、卵巢、精巢组织中均有表达,且在不同组织中的表达水平由高到低依次是：脑>尾鳍>精巢>心、肠、鳔> 卵巢、脾、鳃、肌>肝、肾。本研究证实了GABABR1基因在异育银鲫各组织中的表达的广泛性,且有明显的组织特异性。     

GABAB 受体变构剂药学研究进展

Y-氨基丁酸B受体(GABAB receptor,GABABR)是最具有药理学意义的药物靶点之一,具有复杂而精细的激活机制.传统的GABABR靶点药物开发集中于激动剂和拮抗剂,这类药物受到多种因素的制约,包括较强的副作用、药物代谢困难、机体耐药性明显等.变构剂结合于正构位点之外,能够调节GABABR异源二聚体亚基或结构域间的相互作用.正向变构剂(positive allosteric modulators,PAMs)和负向变构剂(negative allosteric modulators,NAMs)分别可以提高或降低GABABR的活性,并具有较高的特异性和药物安全性,同时还能够保持GABABR信号在时间和空间上的可控性.变构剂为GABABR靶点药物开发提供了新思路.     

GABAB受体变构剂药学研究进展

Y-氨基丁酸B受体(GABAB receptor,GABABR)是最具有药理学意义的药物靶点之一,具有复杂而精细的激活机制.传统的GABABR靶点药物开发集中于激动剂和拮抗剂,这类药物受到多种因素的制约,包括较强的副作用、药物代谢困难、机体耐药性明显等.变构剂结合于正构位点之外,能够调节GABABR异源二聚体亚基或结构域间的相互作用.正向变构剂(positive allosteric modulators,PAMs)和负向变构剂(negative allosteric modulators,NAMs)分别可以提高或降低GABABR的活性,并具有较高的特异性和药物安全性,同时还能够保持GABABR信号在时间和空间上的可控性.变构剂为GABABR靶点药物开发提供了新思路.     

A single subunit (GB2) is required for G-protein activation by the heterodimeric GABA(B) receptor.

Although G-protein-coupled receptors (GPCRs) have been shown to assemble into functional homo or heteromers, the role of each protomer in G-protein activation is not known. Among the GPCRs, the gamma-aminobutyric acid (GABA) type B receptor (GABA(B)R) is the only one known so far that needs two subunits, GB1 and GB2, to function. The GB1 subunit contains the GABA binding site but is unable to activate G-proteins alone. In contrast the GB2 subunit, which does not bind GABA, has an heptahelical domain able to activate G-proteins when assembled into homodimers (Galvez, T., Duthey, B., Kniazeff, J., Blahos, J., Rovelli, G., Bettler, B., Prézeau, L., and Pin, J.-P. (2001) EMBO J. 20, 2152-2159). In the present study, we have examined the role of each subunit within the GB1-GB2 heteromer, in G-protein coupling. To that end, point mutations in the highly conserved third intracellular loop known to prevent G-protein activation of the related Ca-sensing or metabotropic glutamate receptors were introduced into GB1 and GB2. One mutation, L686P introduced in GB2 prevents the formation of a functional receptor, even though the heteromer reaches the cell surface, and even though the mutated subunit still associates with GB1 and increases GABA affinity on GB1. This was observed either in HEK293 cells where the activation of the G-protein was assessed by measurement of inositol phosphate accumulation, or in cultured neurons where the inhibition of the Ca(2+) channel current was measured. In contrast, the same mutation when introduced into GB1 does not modify the G-protein coupling properties of the heteromeric GABA(B) receptor either in HEK293 cells or in neurons. Accordingly, whereas in all GPCRs the same protein is responsible for both agonist binding and G-protein activation, these two functions are assumed by two distinct subunits in the GABA(B) heteromer: one subunit, GB1, binds the agonists whereas the other, GB2, activates the G-protein. This illustrates the importance of a single subunit for G-protein activation within a dimeric receptor.     

Allosteric interactions between GB1 and GB2 subunits are required for optimal GABA(B) receptor function

Recent studies on G-protein-coupled receptors revealed that they can dimerize. However, the role of each subunit in the activation process remains unclear. The gamma-amino-n-butyric acid type B (GABA(B)) receptor is comprised of two subunits: GB1 and GB2. Both consist of an extracellular domain (ECD) and a heptahelical domain composed of seven transmembrane alpha-helices, loops and the C-terminus (HD). Whereas GB1 ECD plays a critical role in ligand binding, GB2 is required not only to target GB1 subunit to the cell surface but also for receptor activation. Here, by analysing chimeric GB subunits, we show that only GB2 HD contains the determinants required for G-protein signalling. However, the HD of GB1 improves coupling efficacy. Conversely, although GB1 ECD is sufficient to bind GABA(B) ligands, the ECD of GB2 increases the agonist affinity on GB1, and is necessary for agonist activation of the receptor. These data indicate that multiple allosteric interactions between the two subunits are required for wild-type functioning of the GABA(B) receptor and highlight further the importance of the dimerization process in GPCR activation.     

A trafficking checkpoint controls GABA(B) receptor heterodimerization

Surface expression of GABA(B) receptors requires heterodimerization of GB1 and GB2 subunits, but little is known about mechanisms that ensure efficient heterodimer assembly. We found that expression of the GB1 subunit on the cell surface is prevented through a C-terminal retention motif RXR(R); this sequence is reminiscent of the ER retention/retrieval motif RKR identified in subunits of the ATP-sensitive K+ channel. Interaction of GB1 and GB2 through their C-terminal coiled-coil alpha helices masks the retention signal in GB1, allowing the plasma membrane expression of the assembled complexes. Because individual GABA(B) receptor subunits and improperly assembled receptor complexes are not functional even if expressed on the cell surface, we conclude that a trafficking checkpoint ensures efficient assembly of functional GABA(B) receptors.     

A captured folding intermediate involved in dimerization and domain-swapping of GB1

Immunoglobulin binding domain B1 of streptococcal protein G (GB1), a small (56 residues), stable, single domain protein, is one of the most extensively used model systems in the area of protein folding and design. The recently determined NMR structure of a quadruple mutant (HS#124F26A, L5V/F30V/Y33F/A34F) revealed a domain-swapped dimer that dissociated into a partially folded, monomeric species at low micromolar protein concentrations. Here, we have characterized this monomeric, partially folded species by NMR and show that extensive conformational heterogeneity for a substantial portion of the polypeptide chain exists. Exchange between the conformers within the monomer ensemble on the microsecond to millisecond timescale renders the majority of backbone amide resonances broadened beyond detection. Despite these extensive temporal and spatial fluctuations, the overall architecture of the monomeric mutant protein resembles that of wild-type GB1 and not the monomer unit of the domain-swapped dimer.     

The point mutation A34F causes dimerization of GB1

The immunoglobulin-binding domain B1 of streptococcal protein G (GB1), a very stable, small, single-domain protein, is one of the most extensively used models in the area of protein folding and design. Variants derived from a library of randomized hydrophobic core residues previously revealed alternative folds, namely a completely intertwined tetramer (Frank et al., Nat Struct Biol 2002;9:877-885) and a domain-swapped dimer (Byeon et al., J Mol Biol 2003;333:141-152). Here, we report the NMR structure of the single amino acid mutant Ala-34-Phe which exists as side-by-side dimer. The dimer dissociation constant is 27 +/- 4 microM. The dimer interface comprises two structural elements: First, the beta-sheets of the two monomers pair in an antiparallel arrangement, thereby forming an eight-stranded beta-sheet. Second, the alpha-helix is shortened, ending in a loop that engages in intermolecular contacts. The largest difference between the monomer unit in the A34F dimer and the monomeric wild-type GB1 is the dissolution of the C-terminal half of the alpha-helix associated with a pronounced slow conformational motion of the interface loop. This involves a large movement of the Tyr-33 side chain that swings out from the monomer to engage in dimer contacts.     

Desensitization of GABA(B) receptor signaling by formation of protein complexes of GABA(B2) subunit with GRK4 or GRK5

We investigated the role of G protein coupled-receptor kinases (GRKs) in the desensitization of GABA(B) receptor-mediated signaling using Xenopus oocytes and baby hamster kidney (BHK) cells. Baclofen elicited inward K(+) currents in oocytes coexpressing heterodimeric GABA(B) receptor, GABA(B1a) subunit (GB(1a)R) and GABA(B2) subunit (GB(2)R), together with G protein-activated inwardly rectifying K(+) channels (GIRKs), in a concentration-dependent manner. Repetitive application of baclofen to oocytes coexpressing GABA(B)R and GIRKs did not change peak K(+) currents in the first and second responses, but the latter responses were significantly attenuated by coexpression of either GRK4 or GRK5 with attenuation efficacy of GRK4 > GRK5. Coexpression of other GRKs including GRK2, GRK3, and GRK6 had no effect on GABA(B) receptor-mediated desensitization processes. In BHK cells coexpressing GRK4 fused to Venus (brighter variant of yellow fluorescent protein, GRK4-Venus) with GB(1a)R and GB(2)R, GRK4-Venus was expressed in the cytosol but was translocated to the plasma membranes by GABA(B)R activation. In BHK cells coexpressing GRK4 fused to Cerulean (brighter variant of cyan fluorescent protein, GRK4-Cerulean) with GB(1a)R and GB(2)R-Venus, fluorescence resonance energy transfer (FRET) analysis demonstrated that GRK4-Cerulean formed a protein complex with GB(2)R-Venus. Immunoprecipitation and Western blot analysis confirmed GB(2)R-GRK4 complex formation. GRK5 also formed a complex with GB(2)R on the plasma membranes as determined by FRET and Western blotting but not GRK2, GRK3, and GRK6. Our results indicate that GRK4 and GRK5 desensitize GABA(B) receptor-mediated responses by forming protein complexes with GB(2)R subunit of GABA(B)R at the plasma membranes.     

Structures of the yeast ribonucleotide reductase Rnr2 and Rnr4 homodimers

Class I ribonucleotide reductases (RNRs) catalyze the reduction of ribonucleotides to deoxyribonucleotides. Eukaryotic RNRs comprise two subunits, the R1 subunit, which contains substrate and allosteric effector binding sites, and the R2 subunit, which houses a catalytically essential diiron-tyrosyl radical cofactor. In Saccharomyces cerevisiae, there are two variants of the R2 subunit, called Rnr2 and Rnr4. Rnr4 is unique in that it lacks three iron-binding residues conserved in all other R2s. Nevertheless, Rnr4 is required to activate Rnr2, and the functional species in vivo is believed to be a heterodimeric complex between the two proteins. The crystal structures of the Rnr2 and Rnr4 homodimers have been determined and are compared to that of the heterodimer. The homodimers are very similar to the heterodimer and to mouse R2 in overall fold, but there are several key differences. In the Rnr2 homodimer, one of the iron-binding helices, helix alphaB, is not well-ordered. In the heterodimer, interactions with a loop region connecting Rnr4 helices alphaA and alpha3 stabilize this Rnr2 helix, which donates iron ligand Asp 145. Sequence differences between Rnr2 and Rnr4 prevent the same interactions from occurring in the Rnr2 homodimer. These findings provide a structural rationale for why the heterodimer is the preferred complex in vivo. The active-site region in the Rnr4 homodimer reveals interactions not apparent in the heterodimer, supporting previous conclusions that this subunit does not bind iron. When taken together, these results support a model in which Rnr4 stabilizes Rnr2 for cofactor assembly and activity.     

A protein contortionist: core mutations of GB1 that induce dimerization and domain swapping

Immunoglobulin-binding domain B1 of streptococcal protein G (GB1), a small (56 residues), stable, single-domain protein, is one of the most extensively used model systems in the area of protein folding and design. Recently, NMR and X-ray structures of a quintuple GB1 core mutant (L5V/A26F/F30V/Y33F/A34F) that showed an unexpected, intertwined tetrameric architecture were determined. Here, we report the NMR structure of another mutant, derived from the tetramer by reverting the single amino acid position F26 back to the wild-type sequence A26. The structure reveals a domain-swapped dimer that involves exchange of the second beta-hairpin. The resulting overall structure comprises an eight-stranded beta-sheet whose concave side is covered by two alpha helices. The dimer dissociates into a partially folded, monomeric species with a dissociation constant of 93(+/-10)microM.     

A cleavable signal peptide enhances cell surface delivery and heterodimerization of Cerulean-tagged angiotensin II AT1 and bradykinin B2 receptor

Heterodimerization of the angiotensin II AT1 receptor with the receptor for the vasodepressor bradykinin, B2R, is known to sensitize the AT1-stimulated response of hypertensive individuals in vivo. To analyze features of that prototypic receptor heterodimer in vitro, we established a new method that uses fluorescence resonance energy transfer (FRET) and applies for the first time AT1-Cerulean as a FRET donor. The Cerulean variant of the green fluorescent protein as donor fluorophore was fused to the C-terminus of AT1, and the enhanced yellow fluorescent protein (EYFP) as acceptor fluorophore was fused to B2R. In contrast to AT1–EGFP, the AT1-Cerulean fusion protein was retained intracellularly. To facilitate cell surface delivery of AT1-Cerulean, a cleavable signal sequence was fused to the receptor’s amino terminus. The plasma membrane-localized AT1-Cerulean resembled the native AT1 receptor regarding ligand binding and receptor activation. A high FRET efficiency of 24.7% between membrane-localized AT1-Cerulean and B2R-EYFP was observed with intact, non-stimulated cells. Confocal FRET microscopy further revealed that the AT1/B2 receptor heterodimer was functionally coupled to receptor desensitization mechanisms because activation of the AT1-Cerulean/B2R-EYFP heterodimer with a single agonist triggered the co-internalization of AT1/B2R. Receptor co-internalization was sensitive to inhibition of G protein-coupled receptor kinases, GRKs, as evidenced by a GRK-specific peptide inhibitor. In agreement with efficient AT1/B2R heterodimerization, confocal FRET imaging of co-enriched receptor proteins immobilized on agarose beads also detected a high FRET efficiency of 24.0%. Taken together confocal FRET imaging revealed efficient heterodimerization of co-enriched and cellular AT1/B2R, and GRK-dependent co-internalization of the AT1/B2R heterodimer.